Quarter
Charts

CONMED CORPORATION

CNMD

CIK 0000816956 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$373M
↑+7.9% +$27Mvs FY2024 (Q4)
Operating Income
$37M
↓-30.2% -$16Mvs FY2024 (Q4)
Net Income
$17M
↓-50.4% -$17Mvs FY2024 (Q4)
Gross Profit
$218M
↑+10.1% +$20Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
38/100
  • Profitability
    9ROIC 6.8% (10% = solid, 20%+ = moat)
  • Liquidity
    82Current Ratio 2.14 (above 1.5 = solid)
  • Leverage
    66D/E 0.69 (under 0.5 = conservative)
  • Efficiency
    30Asset Turnover 0.59x (1.0+ = capital-efficient)
  • Growth
    43Revenue YoY +7.9% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin 9.8% · trend -8.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project CNMD's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

25%

Trailing 3-yr CAGR was 135.3%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$161.57
Total enterprise IV
$5.03B
Diluted shares
0.03B
Terminal PV
$3.91B (78% of total)
Year-5 FCF
$460M
YearProjected FCFDiscounted PV
+1$189M$171M
+2$236M$195M
+3$295M$221M
+4$368M$252M
+5$460M$286M
Terminal$6.29B$3.91B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$20M
investment in PP&E
Dividends paid (TTM)
$25M
cash returned to holders
Stock buybacks (TTM)
—
share count reduction
Stock-based comp (TTM)
$28M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$2.33B
everything owned
Total liabilities
$1.29B
everything owed
Stockholders' equity
$1.03B
shareholder claim
Net debt
$768M
LT debt minus cash

Recent performance · 65 quarters

Revenue↑+7.9% +$27M
$373M
Net Income↓-50.4% -$17M
$17M
Free Cash Flow↑+4.9% +$2M
$41M
Operating Margin↓-5.4pts
9.8%

Drill down

CNMD Sankey

See CONMED CORPORATION's revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

CNMD Charts

65 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

CNMD Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics